	US 12,435,142 B2
	Anti-CTLA4 antibodies and methods of use thereof
Margaret Karow, Waltham, MA (US)
Assigned to Xilio Development, Inc., Waltham, MA (US)
Appl. No. 17/417,244
Filed by Xilio Development, Inc., Waltham, MA (US)
PCT Filed Dec. 26, 2019, PCT No. PCT/US2019/068548 § 371(c)(1), (2) Date Jun. 22, 2021, PCT Pub. No. WO2020/139926, PCT Pub. Date Jul. 2, 2020.
Claims priority of provisional application 62/785,111, filed on Dec. 26, 2018.
Prior Publication US 2022/0064301 A1, Mar. 3, 2022
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01)

CPC C07K 16/2818 (2013.01) [A61K 47/6849 (2017.08); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/40 (2013.01); C07K 2317/52 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/72 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/50 (2013.01)]

16 Claims

1. An anti-CTLA4 antibody comprising a light chain variable (VL) domain and a heavy chain variable (VH) domain, wherein:

the VL domain comprises (i) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 19, (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 20, and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 21; and the VH domain comprises (1) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 22, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 23, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 24; and

wherein the antibody comprises a heavy chain constant region (CH) comprising substitutions S239D and I332E, wherein the amino acid residues are numbered according to EU index as in Kabat.